



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc



Corrigendum

Corrigendum to “Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2” [Bioorg. Med. Chem. 18 (2010) 707]

Stephen Hilton^{a,†}, Sebastien Naud^a, John J. Caldwell^a, Kathy Boxall^a, Samantha Burns^a, Victoria E. Anderson^a, Laurent Antoni^a, Charlotte E. Allen^a, Laurence H. Pearl^b, Antony W. Oliver^b, G. Wynne Aherne^a, Michelle D. Garrett^a, Ian Collins^{a,*}

^a Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK

^b Section of Structural Biology, Chester Beatty Laboratories, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK

The authors regret that the residue ‘Leu309’ was incorrectly labeled in the crystal structures in Figure 5A–D, p712, and should correctly be labeled ‘Val234’. The accompanying text on p712 should read ‘The inhibitor occupied the ATP-binding site of CHK2 and was sandwiched between the hydrophobic side chains of Val234 and Leu354 (Fig. 5A).’

DOI of original article: [10.1016/j.bmc.2009.11.058](https://doi.org/10.1016/j.bmc.2009.11.058)

* Corresponding author. Tel.: +44 208 722 4317; fax: +44 208 722 4216.

E-mail address: ian.collins@icr.ac.uk (I. Collins).

† Present address: The School of Pharmacy, University of London, UK.